-
Mashup Score: 3
Tesla records reveal the automaker has long known far more about the extent of defects than it has disclosed to consumers and safety regulators.
Source: www.reuters.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5MSKCC Investigators #MemorialSloanKettering - 8 month(s) ago
Join the conversation
Source: bsky.appCategories: General Medicine News, Hem/OncsTweet-
Come join me & other @MSKCancerCenter colleagues on @bluesky https://t.co/Di9TlBNN5u https://t.co/sflSeYc6qk
-
-
Mashup Score: 6Miguel Perales MD (@drmiguelperales.bsky.social) - 8 month(s) ago
Chief, Adult BMT Service @memorialsloankettering – Past-President @ASTCT – Past Board Member @NMDP – opinions mine/not my employer’s https://www.mskcc.org/cancer-care/doctors/miguel-angel-perales
Source: bsky.appCategories: General Medicine News, Hem/OncsTweet-
I just joined @bluesky in time for @ASH_hematology #ASH24 - hope to see you there #Medsky https://t.co/WE4fLHpmpA https://t.co/R28itP9HhB
-
-
Mashup Score: 12024 Transplant and Cellular Therapy Options for Non-Malignant Disorders - MSK Continuing Medical Education - Continuing Education (CE) - 11 month(s) ago
MSK Continuing Medical Education, 2024 Transplant and Cellular Therapy Options for Non-Malignant Disorders, 10/24/2024 8:30:00 AM – 10/25/2024 4:15:00 PM, Advancements in therapies for non-malignant hematologic disorders have significantly improved survival rates. However, awareness of the latest innovative treatment options available to patients remains limited among many. The goal of this symposium is to review and discuss cutting-edge treatments for both pediatric and adult patients. Expert faculty will review relevant clinical cases and innovative treatment modalities related to gene therapy and allogeneic stem cell transplantation. The program features a series of didactic and interactive sessions, including: Department of Pediatrics Grand Rounds: Curing Sickle Cell Disease, presented by Akshay Sharma, MBBS, MSc of St. Jude Children’s Research Hospital Department of Medicine Grand Rounds & Dr. Richard O’Reilly Lecture: How we Use Gene Therapy to Save Sickle Cell Disease, presented
Source: mskcc.cloud-cme.comCategories: General Medicine News, Hem/OncsTweet-
RT @wanderingmd: come join us at the non-malignant heme symposium! Register today! https://t.co/LvVbZB40PL #TCT4nonmalignant2024 @MSKC…
-
-
Mashup Score: 14The Movement to Beat Rare Cancers | Cycle for Survival - 1 year(s) ago
Together, let’s bring new and better treatment options to people with cancer. 100% of all money raised directly funds lifesaving rare cancer research at Memorial Sloan Kettering.
Source: secure2.convio.netCategories: General Medicine News, Hem/OncsTweet-
I ride @Cycle4Survival tomorrow! Together as a community, we are getting closer to reaching $375M raised since 2007. Will you consider supporting my fundraising efforts? 100% of every dollar will advance lifesaving rare cancer research at @MSKCancerCenter https://t.co/CR2SQ9TrPD
-
-
Mashup Score: 1
Tesla records reveal the automaker has long known far more about the extent of defects than it has disclosed to consumers and safety regulators.
Source: www.reuters.comCategories: General Medicine News, Hem/OncsTweet-
Tesla blamed drivers for failures of parts it long knew were defective https://t.co/LUXwMnJ741
-
-
Mashup Score: 1
Tesla records reveal the automaker has long known far more about the extent of defects than it has disclosed to consumers and safety regulators.
Source: www.reuters.comCategories: General Medicine News, Hem/OncsTweet-
Tesla blamed drivers for failures of parts it long knew were defective https://t.co/LUXwMnJ741
-
-
Mashup Score: 0
Tesla records reveal the automaker has long known far more about the extent of defects than it has disclosed to consumers and safety regulators.
Source: www.reuters.comCategories: General Medicine News, Hem/OncsTweet-
Tesla blamed drivers for failures of parts it long knew were defective https://t.co/LUXwMnJ741
-
-
Mashup Score: 14ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD) - 2 year(s) ago
The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration’s (FDA) recently granted a …
Source: www.newswire.comCategories: General Medicine News, Hem/OncsTweet-
.@ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD) https://t.co/x8HyHcRRqC
-
-
Mashup Score: 14ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD) - 2 year(s) ago
The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration’s (FDA) recently granted a …
Source: www.newswire.comCategories: General Medicine News, Hem/OncsTweet-
.@ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD) https://t.co/x8HyHcRRqC
-
Tesla blamed drivers for failures of parts it long knew were defective https://t.co/LUXwMnJ741